The Bell Perspective

As Livmark Communities breaks ground on its 457-unit luxury complex, The Collins, it tests a Fort Collins market grappling with an affordability crisis.

Oak Hill Bio is betting on a therapy shelved by a pharma giant. Its new trial for Angelman syndrome tests a disruptive model for rare disease innovation.

A prestigious oncology award is more than a personal accolade. It’s a signal of a shrewd strategy by regional players like Baystate Health to shape the future of medicine from the inside out.

A media tour reveals Aba's green-tech leap. But beyond the impressive drones and pristine vistas lies a masterclass in narrative control by Beijing.

The new 'Pit Stops' collection is more than a fashion drop. It's a savvy play on cultural identity, limited editions, and high-margin nostalgia. Here's why.

Sovol's new M1D printer isn't just another machine. By merging IDEX and Tool Changer tech, it aims to eliminate the massive waste of multi-color printing.

Berkshire Hathaway's acquisition of Taylor Morrison creates a new housing titan. What does this mega-deal signal for the industry and for homebuyers?

As Tricentis captures the top spot in the $6.3B software quality market, its success reveals a deeper trend: the race to build autonomous systems that ensure AI is trustworthy.

A Tokyo innovator just hit Nasdaq via a SPAC. Is its vertically integrated model the key to unlocking the $67B longevity market or just another biotech gamble?

The OC Fair isn't just a summer tradition; it's a finely tuned economic engine. Timothy Bell analyzes how it blends nostalgia with strategic innovation.

A fully-leased, 400,000 sq. ft. zero-carbon industrial park in Halifax, featuring a record speculative lease, confirms the city's rise as a key logistics hub.

Beyond cash prizes, Hainan's 'Volcano Wisdom Summit Cup' is a strategic play to lure global innovators and fast-track its Free Trade Port ambitions.

With a veteran team from Meta and Snowflake and a massive $180M war chest, Glow is betting it can win the AI security arms race with a radical new model.

Peer-reviewed data confirms Telix's theranostic approach for advanced prostate cancer, de-risking its Phase 3 trial and setting the stage for a new competitor.

After a seven-year gauntlet, CorPower Ocean's DNV certification de-risks a long-promised technology, unlocking a new frontier for investors and the grid.

SSR Mining completes its strategic pivot to the Americas, trading its Hod Maden equity for a royalty stream and shedding geopolitical risk for free cash flow.

While markets fret over uncertainty, ASSA ABLOY posts record margins. Timothy Bell dissects its dual-engine strategy of relentless innovation and acquisition.

A father-daughter duo's personal fight against Lyme disease has culminated in a major retail deal, placing their chemical-free tool in Costco's aisles.

ReconAfrica's hydrocarbon discovery promises economic transformation for Namibia, but it also presents a forensic test of the nation's environmental resolve.

Allstate's massive Q2 catastrophe bill is more than a financial headline. It's a stark signal of a volatile new normal where extreme weather reshapes risk.